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Abstract
Drug delivery vehicles can improve the functional efficacy of existing antimicrobial therapies by improving
biodistribution and targeting. A critical property of such nanomedicine formulations is their ability to control
the release kinetics of their payloads. The combination of (and interactions between) polymer, drug, and
nanoparticle properties gives rise to nonlinear behavioral relationships and a large data space. These factors
complicate both first-principles modeling and screening of nanomedicine formulations. Predictive analytics
may offer a more efficient approach toward rational design of nanomedicines by identifying key descriptors
and correlating them to nanoparticle release behavior. In this work, antibiotic release kinetics data were
generated from polyanhydride nanoparticle formulations with varying copolymer compositions, encapsulated
drug type, and drug loading. Four antibiotics, doxycycline, rifampicin, chloramphenicol, and pyrazinamide,
were used. Linear manifold learning methods were used to relate drug release properties with polymer, drug,
and nanoparticle properties, and key descriptors were identified that are highly correlated with release
properties. However, these linear methods could not predict release behavior. Non-linear multivariate
modeling based on graph theory was then used to deconvolute the governing relationships between these
properties, and predictive models were generated to rapidly screen lead nanomedicine formulations with
desirable release properties with minimal nanoparticle characterization. Release kinetics predictions of two
drugs containing atoms not included in the model showed good agreement with experimental results,
validating the model and indicating its potential to virtually explore new polymer and drug pairs not included
in training data set. The models were shown to be robust after inclusion of these new formulations in that the
new inclusions did not significantly change model regression. This approach provides the first steps towards
development of a framework that can be used to rationally design nanomedicine formulations by selecting the
appropriate carrier for a drug payload to program desirable release kinetics.
Keywords
polyanhydrides, degradable biomaterials, drug delivery, drug release kinetics, informatics, data mining
Disciplines
Biochemical and Biomolecular Engineering | Medicinal Chemistry and Pharmaceutics | Nanoscience and
Nanotechnology
Comments
This document is the unedited Author’s version of a Submitted Work that was subsequently accepted for
publication in Molecular Pharmaceutics, copyright © American Chemical Society after peer review. To access
the final edited and published work see DOI: 10.1021/acs.molpharmaceut.8b01272.
Authors
Adam S. Mullis, Scott R. Broderick, Andrea M. Binnebose, Nathan Peroutka-Bigus, Bryan H. Bellaire, Krishna
Rajan, and Balaji Narasimhan
This article is available at Iowa State University Digital Repository: https://lib.dr.iastate.edu/cbe_pubs/371
1A data analytics approach for rational design of 
nanomedicines with programmable drug release
Adam S. Mullis1, Scott R. Broderick2, Andrea M. Binnebose3,4, Nathan Peroutka-Bigus3,4, Bryan 
H. Bellaire3,4,5, Krishna Rajan2,5, and Balaji Narasimhan1,5*
1Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 
50011, United States
2Department of Materials Design and Innovation, University at Buffalo, Buffalo, NY 14260, 
United States
3Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, 
Iowa 50011, United States
4Interdepartmental Microbiology Graduate Program, Iowa State University, Ames, Iowa 50011, 
United States
5Nanovaccine Institute, Iowa State University, Ames, Iowa 50011, United States
KEYWORDS: polyanhydrides, degradable biomaterials, drug delivery, drug release kinetics, 
informatics, data mining
Page 1 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2ABSTRACT 
Drug delivery vehicles can improve the functional efficacy of existing antimicrobial therapies by 
improving biodistribution and targeting. A critical property of such nanomedicine formulations is 
their ability to control the release kinetics of their payloads. The combination of (and interactions 
between) polymer, drug, and nanoparticle properties gives rise to nonlinear behavioral 
relationships and a large data space. These factors complicate both first-principles modeling and 
screening of nanomedicine formulations. Predictive analytics may offer a more efficient 
approach toward rational design of nanomedicines by identifying key descriptors and correlating 
them to nanoparticle release behavior. In this work, antibiotic release kinetics data were 
generated from polyanhydride nanoparticle formulations with varying copolymer compositions, 
encapsulated drug type, and drug loading. Four antibiotics, doxycycline, rifampicin, 
chloramphenicol, and pyrazinamide, were used. Linear manifold learning methods were used to 
relate drug release properties with polymer, drug, and nanoparticle properties, and key 
descriptors were identified that are highly correlated with release properties. However, these 
linear methods could not predict release behavior. Non-linear multivariate modeling based on 
graph theory was then used to deconvolute the governing relationships between these properties, 
and predictive models were generated to rapidly screen lead nanomedicine formulations with 
desirable release properties with minimal nanoparticle characterization. Release kinetics 
predictions of two drugs containing atoms not included in the model showed good agreement 
with experimental results, validating the model and indicating its potential to virtually explore 
new polymer and drug pairs not included in training data set. The models were shown to be 
robust after inclusion of these new formulations in that the new inclusions did not significantly 
change model regression. This approach provides the first steps towards development of a 
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3framework that can be used to rationally design nanomedicine formulations by selecting the 
appropriate carrier for a drug payload to program desirable release kinetics.
1. INTRODUCTION
Intracellular bacterial infections are challenging to treat using traditional antimicrobial 
therapies due to the difficulty in achieving high enough local drug concentration for 
antimicrobial activity without inducing host cell toxicity.1 Elimination of soluble drugs through 
host metabolism and excretion pathways act to reduce bioavailable amounts of antimicrobials 
requiring repeated dosing to maintain therapeutic concentrations to mitigate the development of 
antibiotic resistant in pathogens.2,3 Drug delivery vehicles can improve the efficacy and potency 
of antimicrobials by altering the drug biodistribution with improved intracellular localization and 
delivery of cargo to the pathogen’s intracellular niche within host cells.4,5 Biodegradable 
polyanhydride nanoparticles show passive targeting and payload stabilization properties that 
make them uniquely suited for antibiotic delivery for intracellular infections.4,6 These particles 
are internalized efficiently by phagocytic cells using multiple mechanisms, and have been used 
to deliver antibiotics to kill intracellular Brucella abortus.7 Additionally, polyanhydride 
nanoparticles mediated efficient killing of filarial parasites by co-delivering an antiparasitic with 
an antibiotic targeting an intracellular endosymbiotic bacterium that supports parasite health and 
reproduction.8 
A key feature of the effectiveness of these nanomedicine formulations is their ability to control 
payload release rate, however rationally designing nanomedicines with programmable release 
remains elusive. Release kinetics are influenced by drug distribution within a device and/or a 
particle, which is in turn influenced by polymer-drug thermodynamic interactions.9–11 These 
interactions give rise to nonlinear release behavior which is difficult to predict a priori. 
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4Screening nanomedicine formulations is challenging as polymer and nanoparticle properties 
(e.g., polymer chemistry, nanoparticle size, polydispersity, release kinetics, and encapsulation 
efficiency) yield a large number of additional variables beyond drug-specific properties. This 
large dataspace, coupled with the multiple length scales at play, poses difficulties for 
generalizing conclusions to other nanoparticle systems and impedes first principles modeling of 
nanoparticle behavior.12,13 Hierarchical modeling may be a more efficient approach for such 
systems, wherein key descriptors are identified and correlated to performance parameters.
Informatics methods encompass several tools for such hierarchical modeling. Data mining 
techniques can deconvolute complex behavior, unraveling relationships that lie on non-Euclidian 
surfaces,14 which enables pattern recognition and prediction through the development of 
quantitative structure-property relationships (QSPRs).15 To this end, previous informatics 
analyses from our laboratories has enabled identification of polyanhydride chemistry and 
structural factors that influence protein release from films16 and enable pathogen-mimicking 
nanoparticle processing by immune cells.17–20 
The focus of this work was to develop an informatics-based framework that determines how 
polymer, drug, and nanoparticle characteristics influence drug encapsulation efficiency and 
release kinetics. We sought to generate predictive models that can virtually test potential new 
polymer and drug combinations for desirable release kinetics. Our long-term goal is to develop a 
predictive analytics framework to enable rational design of nanomedicine formulations for 
different types of therapeutic and prophylactic applications. 
2. MATERIALS AND METHODS
2.1. Materials. Sebacic acid (SA) was purchased from Sigma Aldrich (St. Louis, MO). 
Triethylene glycol, 4-p-hydroxybenzoic acid, 1- methyl-2-pyrrolidinone, and 1,6-dibromohexane 
Page 4 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5were purchased from Sigma Aldrich for 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
and 1,6-bis(p-carboxyphenoxy)hexane (CPH) monomer synthesis. Potassium carbonate, 
dimethyl formamide, toluene, acetonitrile, acetic acid, sulfuric acid, N,N-dimethylacetamide, and 
acetic anhydride were purchased from Fisher Scientific (Fairlawn, NJ) for monomer and polymer 
synthesis. 4-p-fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, UK) for use in 
monomer synthesis. Methylene chloride, pentane, and hexanes were purchased from Fisher 
Scientific for polymer purification and nanoparticle synthesis. Doxycycline (DOX), rifampicin 
(RIF), and pyrazinamide (PZA) were purchased from Sigma Aldrich, and chloramphenicol 
(CAM) was purchased from Fisher Scientific. Meropenem (MEM) was purchased from Ark 
Pharm, Inc. (Arlington Heights, IL) and ceftazidime (CAZ) was purchased from Acros Organics 
(NJ). 1H NMR analysis used deuterated chloroform purchased from Cambridge Isotope 
Laboratories (Andover, MA). Drug quantification used UV-transparent microplates from Greiner 
Bio-One (Kremsmünster, Austria), HPLC grade acetonitrile, methanol, and tetrahydrofuran from 
Fisher Scientific, and phosphoric acid from Sigma Aldrich.
2.2. Polymer and nanoparticle synthesis. CPTEG and CPH diacid were synthesized as 
described previously.10,21,22 CPTEG:CPH and CPH:SA copolymers were synthesized as 
described previously.10,21 Briefly, monomers were weighed in appropriate molar ratios and added 
to a round bottom flask. The monomers were acetylated in excess acetic acid at 125°C for 30 
min, and rotary evaporation was used to remove excess solvent from the resulting prepolymer. 
CPTEG:CPH was reacted for six hours at 140°C at <0.1 Torr and CPH:SA was reacted for 30 
min at 180°C at <0.3 Torr. Polymers were purified by precipitation in chilled hexanes. 
Copolymer composition and number average molecular weight (Mn) was confirmed from 1H 
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6NMR spectra acquired on a Varian MR-400 (Varian, Inc. Palo Alto, CA) and thermal properties 
of the copolymers was characterized by DSC (Q2000, TA Instruments, New Castle, DE). 
Antibiotic-loaded nanoparticles were synthesized as described previously.7,8 Polymer and drug 
were weighed in separate scintillation vials at appropriate %w/w ratios. Enough methylene 
chloride to dissolve the polymer at 20 mg/mL was added to the drug vial to dissolve/disperse the 
drug, then transferred to the polymer vial. The combined drug and polymer solution was poured 
into a pentane antisolvent bath at room temperature (CPH:SA) or -10°C (CPTEG:CPH) at a 
solvent:anti-solvent ratio of 1:250 and nanoparticles were recovered by vacuum filtration. 
CPTEG:CPH nanoprecipitation was carried out in a cold room at 4°C. A total of 68 
nanoformulations were tested, spanning drug loadings between 1% and 20% loading (% w/w). 
All drugs were tested in 20:80 CPH:SA and 20:80 CPTEG:CPH nanoparticles, and rifampicin 
was additionally tested in 10:90, 30:70, and 50:50 CPTEG:CPH. 1H NMR spectra of empty 
20:80 CPTEG:CPH and 20:80 CPH:SA nanoparticles indicated undetectable amounts of 
methylene chloride and trace amounts of pentane (data not shown). 
To validate the informatics analysis, nanoparticles encapsulating meropenem or ceftazidime 
were synthesized using a high-throughput method adapted from Goodman et al.23 Briefly, 
polymer and drugs were dissolved/dispersed in methylene chloride and dispensed via high-
throughput robot into 10 mL borosilicate tubes at a final polymer concentration of 20 mg/mL. 
The robot sonicated and dispensed the combined polymer and drug solution into 50 mL conical 
polypropylene tubes containing 45 mL pentane (1:18 solvent:anti-solvent ratio) at the 
temperatures listed above. Multiple particle batches were pooled and recovered by vacuum 
filtration. Scanning electron microscopy (SEM, FEI Quanta 250, Hillsboro, OR) was used to 
image all nanoparticles, and size distributions were calculated using Fiji image analysis 
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7software24 and the ParticleSizer plugin script for Fiji. Nanoparticle zeta potential was measured 
using a Zetasizer Nano (Malvern Instruments Ltd., Worcester, UK). 
2.3. Drug release kinetics. Nanoparticles (9-11 mg) were dispersed in 0.5 mL PBS, pH 7.4 and 
suspended by sonication (VCX 130 PB, Sonics & Materials, Inc., Newtown, CT). At each time 
point, the nanoparticles were pelleted by centrifugation and supernatant was collected for drug 
quantification. Fresh PBS was added to maintain perfect sink conditions and the nanoparticles 
were dispersed by sonication. At the end of the release experiment, 40 mM sodium hydroxide 
was added to accelerate polymer degradation and extract the remaining encapsulated drug as 
described previously.25
The drug mass released at each time point was determined by spectrophotometry (SpectraMax 
M3, Molecular Devices, San Jose, CA) and UV-HPLC (1200 series, Agilent Technologies, Santa 
Clara, CA). Doxycycline, rifampicin, and chloramphenicol were quantified by absorbance in 
UV-transparent 96-well plates at 350, 333, and 293 nm, respectively. Pyrazinamide release and 
base extraction samples were separated using a Phenomenex Kinetex 2.6-micron C18 100Å 
100x4.6mm column and a 30:5:65 acetonitrile:methanol:water mobile phase adjusted to pH 5.2 
with phosphoric acid.26 The flow rate was 0.6 mL/min and pyrazinamide was quantified at 268 
nm. Meropenem and ceftazidime release and base extraction samples were separated using a 
Zorbax Eclipse XDB-C8 5-micron 4.6x150 mm column, monitoring at 299 nm and 246 nm, 
respectively. Meropenem release samples used a mobile phase gradient ramping from 0.1/99.9 
(%v/v) methanol/water to 50/50 over 15 min. Meropenem base extraction samples used a 
gradient ramping from 0.1/99.9 acetonitrile 0.1% trifluoroacetic acid/ water 0.1% trifluoroacetic 
acid to 50/50 over 15 min. Ceftazidime release samples used a mobile phase protocol with an 
isocratic step at 0.1/99.9 methanol/water for 5 minutes followed by a gradient ramping to 50/50 
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8over 10 min. Ceftazidime base extraction samples used an isocratic step at 15/85 from 0.1/99.9 
acetonitrile 0.1% trifluoroacetic acid/ water 0.1% trifluoroacetic acid for 1 min followed by a 
gradient ramping to 40/60 over 5 min. All meropenem and ceftazidime HPLC protocols used a 
flow rate of 1 mL/min.
The small mass of drug and large volume of antisolvent used in nanoparticle synthesis render the 
non-encapsulated drug concentration below the limit of detection of the analytical methods used 
in this study. Therefore encapsulation efficiency (EE) was calculated from the cumulative sum of 
detected drug mass released in PBS and base extraction samples using Eq. 1.25 In a minority of 
formulations >100% EE was observed, which could arise from the presence of drug 
nanocrystals27 (which was not detected on nanoparticle surfaces by SEM), gravimetric 
inaccuracies due to static charge of the nanoparticles, or residual error in the drug concentration 
quantification assays. Drug release kinetics are presented as fraction released, where the 
cumulative drug mass release is normalized by the total encapsulated drug mass. Prism 7 
(Graphpad Software, La Jolla, CA) was used to generate release kinetics figures.
Eq. 1)
𝐸𝐸100% = 𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑑𝑟𝑢𝑔 𝑚𝑎𝑠𝑠 𝑓𝑟𝑜𝑚 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 & 𝑏𝑎𝑠𝑒 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛
𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑚𝑎𝑠𝑠 ∗ 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛(𝑤𝑡𝑤𝑡)
2.4. Informatics analysis. Release behavior parameters, along with polymer, drug, and 
nanoparticle properties, were normalized and mean-centered. Three different informatics 
approaches were integrated and applied to analyze the data in this work. Linear manifold 
learning approaches, such as principal component analysis (PCA),28–30 permit us to identify the 
right projection of data from which meaningful features associated with the input data can be 
identified. PCA performs an eigenvector decomposition and defines a new set of linear 
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9combinations of descriptors which maximize the amount of unique information in a minimal set 
of orthogonal axes, termed principal components (PCs). The original data is decomposed into 
two matrices of interest for this work: the scores and loadings. The scores describe the different 
conditions (i.e., nanoparticle and drug chemistry), while the loadings describe the different 
descriptors and properties. The interpretation of these matrices is provided here with the relevant 
results, and an additional term called the variable importance projection (VIP) is calculated from 
the loadings matrix using Eq. 2. 
Eq. 2)
𝑉𝐼𝑃 = 𝑃𝐶𝑇𝑥 ∗ 𝑃𝐶𝑖𝑥∑𝑃𝐶𝑇𝑥 ∗ 𝑃𝐶𝑖𝑥
In this case, x = 5 because 5 PCs captured >90% of the variance in the data. The analysis was 
performed for T = encapsulation efficiency, drug released @2 h, and fraction released/day 
(Figure 6). Partial Least Squares (PLS) is a multi-linear regression approach which accounts for 
co-linearity in the data, and therefore limits bias and develops more robust quantitative 
relationships.31–34 PLS performs separate PC analyses on the predictor variables (i.e., descriptors) 
and the predicted variables (i.e., properties). These therefore represent linear manifold learning 
approaches which provide qualitative and quantitative design relationships. 
In order to model the drug release properties accurately and robustly, we found that non-linearity 
needed to be accounted for in the modeling. Therefore, we first developed non-linear 
parameterization of the data through non-linear manifold learning, based on graph theory, using 
the Isomap algorithm.14,35 This approach generates a graph connecting data points on a high 
dimensional space to their nearest neighbors, mapped out in the high dimensional space, and then 
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10
fit to a low dimensional manifold. The assumption here is that the graph Euclidean distance 
between the points in high dimensions closely approximates the curvilinear distances along the 
low dimensional manifold. Through dimensionality reduction the manifold unravels into two or 
three dimensions allowing it to be visualized. The result of such dimensionality reduction is a 
weighted graph of the original data points where the edges are weighted according to the 
geodesic distances. Like in PCA, we develop a set of parameters for each set of conditions, 
although in this case the parameters are based on a non-linear combination of descriptors.
3. RESULTS
3.1. Building descriptor library. To generate the data set, we focused on nanoparticles 
composed of CPTEG, CPH, and SA copolymers (Figure 1 a,b). Nanoparticles synthesized from 
these polyanhydride copolymers have been shown to kill intracellular bacteria because of their 
high internalization rates by phagocytic cells,7,36 localization in intracellular compartments that 
harbor these bacteria,17,36 and improved antimicrobial activity of encapsulated drugs.6–8 In 
addition to the structural descriptors defined by Li et al.,16 we included molecular weight and 
compositional data from 1H NMR and thermal characterization from DSC analysis. The release 
kinetics of four antibiotics, doxycycline (Figure 1c), rifampicin (Figure 1d), chloramphenicol 
(Figure 1e), and pyrazinamide (Figure 1f), were studied. The choice of the drug library was 
motivated by multiple factors. These drugs were selected due to their diversity of molecular 
weight, chemical structure, and hydrophobicity, among other physicochemical differences. All 
are FDA-approved drugs and belong to separate antibiotic classes, target distinct bacterial 
structures, and have well-characterized pharmacokinetics/pharmacodynamics. Experimental and 
predicted physicochemical properties for each of these drugs were gathered from the Drugbank 
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11
database.37 Predicted drug properties from this database were calculated by ALGOPS and 
ChemAxon methodologies.
These drugs were encapsulated in polyanhydride nanoparticles by flash nanoprecipitation, and 
zeta potential, size distributions, and polydispersity index were obtained. Release profiles and 
encapsulation efficiencies were obtained from in vitro experiments in PBS, pH 7.4 (Figure 2). 
Figure 2 shows representative release kinetics data for multiple drugs, selected from a total of 68 
nanoformulations that were tested. The formulations depicted in Figure 2 were selected to show 
the diversity of release behavior in the data set. CPH:SA-doxycycline nanoformulations tended 
to show a higher burst than CPTEG:CPH nanoformulations, and the lower loading in the 
CPH:SA nanoformulations tended to have a greater sustained release slope (Figure 2a). The 
chemistry trend was reversed in the rifampicin nanoformulations, where the CPTEG:CPH 
chemistries tended to show a higher burst release than the CPH:SA chemistries, and increasing 
the loading increased the burst (Figure 2b). For chloramphenicol, both 20:80 CPH:SA and 
CPTEG:CPH nanoformulations tended to generate a large burst release followed by a slow rate 
of drug release (Figure 2c). Pyrazinamide formulations generated a large burst from the 20:80 
CPH:SA nanoparticles followed by a steady rate of drug release (Figure 2d). In contrast, the 
20:80 CPTEG:CPH nanoparticles encapsulating pyrazinamide showed a small burst and slow 
rate of drug release and did not release more than 20% of the payload in one week. These results 
add to the body of literature9–11,38 that indicates that copolymer chemistry, drug type, and drug 
loading influence drug release kinetics from biodegradable particles and other devices.
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12
Figure 1. Polymer and antibiotic chemical structures. (a,b) Structures of CPH:SA (a) and 
CPTEG:CPH (b) copolymers, where m and n are the number of repeats for each unit. (c-f) 
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13
Structure of doxycycline (DOX, a), rifampicin (RIF, b), chloramphenicol (CAM, c), and 
pyrazinamide (PZA, d).
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Figure 2. Representative antibiotic release kinetics from nanoparticles encapsulating 
doxycycline (DOX, a), rifampicin (RIF, b), chloramphenicol (CAM, c), and pyrazinamide (PZA, 
d). The depicted nanoformulations represent a subset of the 68 formulations tested and were 
selected to display the diversity of release behavior in the data set. Data are presented as mean  
SD. Error bars are not depicted in cases where the error bar height is smaller than the symbol. 
Release profiles were parameterized into two-hour burst, one day burst, and 2-7 day sustained 
release slope. 
Table 1. Representative antibiotic release properties. FR (2h) fraction released in two-hour 
burst, FR (24h) fraction released in 24-hour burst. Data are presented as mean ± SD.
 
3.2. Identifying Factors that Influence Drug Release. The drug release profiles were 
parameterized using three attributes: (i) fraction released at two hours (FR (2h)); (ii) fraction 
released in one day (FR (24h)), both of which characterized the burst effect; and (iii) the slope of 
the release profile between 2 and 7 days to characterize the sustained release (Table 1). The 
normalized and mean-centered data are represented in the form of a heat map to provide an 
overview and to ensure that no outliers are biasing the results (Figure 3, Table S1-2). In this step, 
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no data specific to particle chemistry was included so as to not bias the analysis. A clustering 
analysis, based on Euclidian distance, was used to visualize broad trends in the data set between 
descriptors and nanoformulations, and is represented in Figure 3 by dendrograms which define 
the correlative indices. The clustering along the y-axis of Figure 3 can be visualized as plotting 
each nanoformulation in multidimensional space, where each dimension is a different descriptor. 
Encompassing n-dimensional “spheres” are defined at the locations of the nanoformulations, and 
as the radii of the spheres increase additional nanoformulations are encompassed. The relative 
sphere size needed to encompass multiple descriptors is comparable to the height of the branch 
in the dendrogram. Nanoformulations or descriptors grouped lower in the dendrograms are likely 
to show relatively strong, positive correlations. Branches higher in the dendrograms are more 
likely to show weak, positive correlations or inverse correlations.
From Figure 3, we find that the primary difference is between CPH:SA and CPTEG:CPH, given 
that the two chemistries branch off at the lowest correlation node. Therefore, particle chemistry 
is the key discriminator for nanoformulation behavior. Within each node, the compounds then 
group based on drug type, and then finally branch off based on theoretical drug loading and 
molar monomer ratios within the copolymer. This defines the order of importance on release 
properties with CPH:SA versus CPTEG:CPH as the most important and the theoretical drug 
loading having less importance. For CPH:SA nanoparticles, rifampicin and pyrazinamide 
grouped together strongly, whereas doxycycline and chloramphenicol grouped together within 
the CPTEG:CPH chemistries. The CPTEG:CPH-chloramphenicol and -pyrazinamide 
nanoformulations clustered together, and diverged from the CPTEG:CPH-rifampicin and -
doxycycline nanoformulations. Considering correlations to the release properties, the fraction 
released at two hours and 24 hours are strongly correlated with the polymer melting point (Tm) 
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and zeta potential. The fraction released/day clustered with nanoparticle diameter and PDI 
polymer DOP and Mn. The relatively low branching of these properties in the dendrogram 
indicates moderate to strong correlation. Encapsulation efficiency (EE) was most strongly 
correlated with water solubility, followed by fraction released/day. This (weak) correlation to 
water solubility is expected, as incompatibility between polymer and drug 
hydrophobicity/hydrophilicity can result in drug partitioning more strongly in the antisolvent 
than the polymer matrix. The drug release properties (burst release, slope of release, and 
encapsulation efficiency) appeared relatively isolated from each other within the dendrogram, 
suggesting potential for independent control of these properties in designing nanoformulations.
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Figure 3. Representation of correlations in data using Euclidian distance-based clustering, with 
the dendrograms defining the degree of correlation (i.e., branches at the bottom of the 
dendrogram have high correlation and correlation decreases as moving along the branches). 
From the dendrograms, the key discriminators among nanoformulations (vertical axis) in the 
order of importance are carrier chemistry (CPTEG:CPH versus CPH:SA), drug type, and 
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theoretical drug loading. Concerning correlations between drug release properties and descriptors 
(horizontal axis), nanoparticle burst release (FR (2hr) and FR (24 hr)) was most strongly 
correlated with zeta potential and drug melting point. The release slope was most strongly 
correlated with the nanoparticle and polymer size properties. Encapsulation efficiency was most 
strongly correlated with the water solubility of the drug. That these data fall within comparable 
ranges demonstrates the robustness of the method and data set, enabling interrogation of 
nanoformulation behavior. Drug abbreviations: doxycycline (DOX), rifampicin (RIF), 
chloramphenicol (CAM), and pyrazinamide (PZA). Raw and processed input data are included in 
Tables S1-2.
A dimensionality reduction analysis, specifically principal component analysis (PCA), was then 
applied to the data of Figure 3, with descriptors specific to the particle and drug chemistry added 
to the data set (Table S3). Plots of formulation mapping and descriptor mapping within the 
dimensionally-reduced space are shown in Figures 4 and 5, respectively. In these figures, the 
principal components (PC) are ordered in terms of decreasing variability captured. PC1, the most 
important PC, captured particle chemistry properties (41.3%); therefore, differences in particle 
chemistry descriptors explain more variance in release behavior than other descriptor sets. The 
next most important PC, PC2, captured differences in drug-specific descriptors (27.9%). The 
scores plot (Figure 4), which maps individual nanoparticle formulations onto these PC’s (which, 
between them, allow us to reliably capture correlations in those two dimensions), shows a clear 
separation between CPTEG:CPH and CPH:SA particle chemistries. Within each polymer,  
doxycycline, chloramphenicol, and pyrazinamide clustered together, whereas rifampicin 
formulations formed a cluster isolated from the other drugs, indicating potentially different types 
of interactions with the particle carriers.
Page 19 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20
The loadings plot (Figure 5), which maps the descriptor variables onto the PC’s shows that the 
role of the particle and the drug bank descriptors have been isolated (i.e., particle data lies along 
the PC1 axis and drug bank data is along the PC2 axis). Given that PC1 is the most important 
axis, we are capturing that the particle chemistry is the critical characteristic for predicting 
particle release behavior. The drug release properties do not adhere exclusively to either PC1 or 
PC2 axes, indicating that they are influenced by both polymer and drug characteristics. The 
ability to isolate the different controls allows us to assess, model, and design by the material 
characteristics.
 
Figure 4. PCA scores plot. PC1 captures differences due to particle chemistry (10:90 
CPTEG:CPH in blue, 20:80 CPTEG:CPH in black, and >30:<70 CPTEG:CPH in green) and PC2 
captures the differences due to drug. There is a clear separation of formulations due to different 
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chemistries, with a demonstrated capability to isolate the effects of particle chemistry from drug 
properties. PC1 and PC2 captured 43.1% and 27.9% of variability, respectively. Drug 
abbreviations: doxycycline (DOX), rifampicin (RIF), chloramphenicol (CAM), and 
pyrazinamide (PZA). Raw input data are provided in Table S3.
Figure 5. PCA loadings plot. Particle descriptors lie along the PC1 axis and drug descriptors lie 
along the PC2 axis. Drug release properties lie along both axes, indicating some dependence on 
both particle and drug descriptors. PC1 and PC2 captured 43.1% and 27.9% of variability, 
respectively. Raw input data are provided in Table S3.
To further quantify the correlation between descriptors and release properties, we calculated the 
VIP. In all, a total of 36 descriptors were used in the VIP analysis (as shown in Table 2), 
describing nanoparticle (1-3), polymer (4-13), and drug properties (14-36). The encapsulation 
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efficiency was most strongly correlated with zeta potential (-), % Cl (drug) (+), % O (drug) (+), 
Tm,drug (-), predicted water solubility (-), pKa (strongest base) (-), and drug rotatable bond count 
(+). As seen in Figure 3, the two-hour burst and slope of release were highly correlated with each 
other, and showed similar correlations with the descriptors. Both the two-hour burst and slope of 
release were most strongly correlated with % Cl (drug) (+), % O (drug) (+), water solubility (-), 
% N (drug) (-), pKa (strongest acid) (-), and rotatable bond count (+). The identification of 
several highly correlated descriptors allows for reduction of the descriptor space to a minimum 
number and defines the number of descriptors necessary for performing high throughput 
calculations. This minimization is an important objective in computational modeling to improve 
model robustness. The purpose of VIP analysis is to assess the descriptors that contribute 
significant information as well as to identify correlated descriptors. While we identify the drug-
related descriptors as having the highest individual impact, the particle-related descriptors 
collectively contribute the largest amount of information as seen in Figure 4.
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Figure 6. Variable importance projection of descriptors with respect to drug release properties. 
Descriptors are listed in Table 2. Positive VIP values correspond to positive correlation, and 
negative values to inverse correlation. 
Table 2. List of descriptors used in VIP analysis.
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3.3. Modeling release behavior. Beyond only observing the correlation of data, we wanted to 
identify similarities and design pathways between the various nanoformulations. This 
connectivity defines samples which have the most similar behavior and can provide information 
on potential replacements and design. In order to accomplish this, we performed a graph theory 
analysis (Figure 7). For the CPH:SA particle chemistries, there is a high connectivity (illustrated 
by black lines) and tight clustering within individual drugs. For the CPTEG:CPH particle 
chemistries, chloramphenicol,  doxycycline, and pyrazinamide showed a high internal 
connectivity, but rifampicin branched out significantly. Each drug showed some degree of 
connectivity between the CPH:SA and CPTEG:CPH particle chemistries and doxycycline 
appeared to be the most interconnected across particle chemistries. 
The degree of similarity can be defined by the number of connections required to connect two 
points. The distance along the two-dimensional projection also indicates the similarity of 
formulations. Pyrazinamide and chloramphenicol generated the least similarity in release 
behavior, as they required 4-6 connections, and lie far from each other along the projection. 
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Within each particle chemistry, doxycycline showed the most similarity to rifampicin and 
pyrazinamide, and rifampicin showed the most similarity to doxycycline and chloramphenicol. 
The branched region of the CPTEG:CPH-rifampicin nanoformulations indicates some 
dissimilarity from the other rifampicin nanoformulations and some unique behavior that will 
need to be explored more systematically using experiments. Of note, the rifampicin formulations 
with altered molar composition of CPTEG:CPH (from the 20:80 that makes up most of the data 
set) showed high similarity to the 20:80 CPTEG:CPH nanoformulations within the cluster. This 
would suggest that nano-carrier copolymer compositions can be interchanged within these 
rifampicin-loaded formulations without major impact. 
This graph theory mapping in Figure 7 yielded notably different drug clustering within each 
nano-carrier chemistry compared to PCA (Figure 4). Rifampicin and chloramphenicol 
formulations are closely related in this map, while they were distant from each other in the PCA 
scores plot. Strikingly, chloramphenicol and pyrazinamide are most distant in the graph theory 
map, while they were clustered closely in the PCA scores plot. These clustering differences are 
likely due to PCA’s limited ability to capture non-linear relationships. Non-linear modeling 
techniques like graph theory are better equipped to capture the non-linear release behavior 
arising from interactions between polymer and drug properties. In summary, the graph theory 
mapping defined similarity and connectivity between different nanoparticle formulations, while 
capturing non-linearity in relationships that can be lost in linear analysis.
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Figure 7. Graph theory map of formulation connectivity of release properties. Similarity 
between points is defined as the number of connections (solid lines) required to connect points. 
CPH:SA chemistries are represented by orange squares, while CPTEG:CPH chemistries are 
represented by circles (10:90 CPTEG:CPH in blue, 20:80 CPTEG:CPH in black, and >30:<70 
CPTEG:CPH in green) This represents an approach for building a set of non-linearly derived 
parameters for performing high-throughput predictions. This approach was applied to a reduced 
descriptor set in order to develop a parameterization of the data, which ensures robustness by 
minimizing the number of input parameters, while incorporating non-linear relationships and 
maximizing variance in the data. Drug abbreviations: doxycycline (DOX), rifampicin (RIF), 
chloramphenicol (CAM), and pyrazinamide (PZA).
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As PCA projects data onto a linear manifold, it has difficulty explaining non-linear relationships. 
To this end, PCA demonstrated insufficient capability to accurately predict release properties in 
this data set. By contrast, graph theory can be used to project the data onto a non-linear manifold. 
This provides high-throughput modeling that accounts for non-linearity without requiring so 
many terms as to reduce the robustness of analysis. Therefore, the input into the predictions 
defines the graph theory values of Figure 7, which reflects a non-linear combination of 
descriptors, and a multi-linear regression between these values and the drug release properties 
was developed. It should be noted that the drug release properties were not included in the non-
linear parameterization used for the prediction input, because that would result in predicting a 
property as a function of itself. The result of the high throughput modeling is shown in Figure 8. 
This represents a model with non-linear parameters that are a function of nanoparticle chemistry 
and theoretical drug loading and is defined generally so as to be applied to a wide range of 
chemistries. These models are fairly accurate, with R2 values ranging between 70.0% and 75.5%. 
Cross validation was applied to ensure an even trade-off between robustness and accuracy. Since 
these methods are based on descriptors that can be generated for potential new nanoparticle 
formulations, the models provide a method to virtually explore a large search space. This method 
can guide experimentation by predicting target properties for a desired release profile, suggesting 
chemistries that match the targeted properties for testing.
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Figure 8. Graph theory high-throughput modeling of drug release properties. The horizontal axis 
is the experimental measurements. The vertical axis is the predicted encapsulation efficiency (a), 
2-hour burst release (b), 24-hour burst release (c), and the d2-d7 release profile slope values from 
our model based on the reduced descriptor set. These calculations are based on a new hybrid 
informatics approach where non-linear manifold projections serve as the input, thereby 
accounting for greater complexity in descriptor-property relationships while also increasing the 
robustness of the models. The models are reasonably accurate for all tested release properties.
3.4. Model validation. To evaluate the robustness and accuracy of the multilinear models, 
nanoparticles encapsulating two new antibiotic drugs (not included in the training data set), 
meropenem and ceftazidime, were synthesized and characterized. Importantly, these drugs 
contain sulfur atoms (Figure S4) which are not present in the four drugs used in the original 
model training. The models in Figure 8 were used to predict the release properties for these new 
formulations (Table 3). Based on these predictions, it is expected that all eight formulations 
would show a high (>80%) burst release at 2h and 24h and minimal sustained release over d2-d7. 
With the exception of the 20:80 CPH:SA–meropenem formulation, all other nanoformulations 
are expected to show near-100% encapsulation efficiency. 
Strikingly, these predictions match experimental results closely. These new nano-formulations 
displayed similar release profiles characterized by a >90% burst release within two hours, 
followed by small amounts of drug released over the following two weeks (Figure S5, Table 3). 
For this data set, the models tended to under-predict the burst release and over-predict the 
sustained release behavior of the nano-formulations. The EE model was relatively accurate for 
20:80 CPH:SA formulations, within 5%-20% of the measured EE’s. The EE model showed more 
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deviation from measured values for 20:80 CPTEG:CPH formulations, at circa 15-35% 
differences from the experimental values. 
Table 3. Parameterized release properties of nanoparticles encapsulating two drugs (meropenem 
and ceftazidime) not included in training data set. FR (2h) fraction released in two-hour burst, 
FR (24h) fraction released in 24-hour burst. 
To test the robustness of the models when adding new, untrained chemistries, eight nano-
formulations were included in the models (compositional percentages were calculated including 
sulfur atoms, but without a separate descriptor for sulfur) and new regressions were calculated. 
We found R2 values for EE, FR (2h), FR (24h) and d2-d7 slope after these inclusions to be 
74.3%, 75.5%, 69.9%, and 74.6%, respectively. The small changes in regression from the 
original model data in Figure 8 indicates that the analytics methodology was able to incorporate 
new drug chemistries with minor impacts on the models. This confirms the robustness of the 
model and its capability to screen drug and polymer chemistries not included in the model 
development.
4. DISCUSSION
Due to the wide diversity of microbial infections, nanomedicines need to be customizable. 
Infections that are responsive to antibiotics may benefit from sustained release-skewing 
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formulations by leveraging the dose sparing properties, limiting the risk of off-target effects, 
reducing the number of administrations, and enhancing patient compliance.4,8,39 Polyanhydride 
nanoparticles represent an attractive and adaptable nanomedicine platform by virtue of their 
tunable degradation and payload release rates,25,40 high biocompatibility,41,42 and efficient 
internalization by phagocytic cells.7
Predictive analytics approaches have the potential to accelerate nanomedicine clinical 
translation, but the application of such informatics and data mining techniques to nanomedicine 
design has been slow to develop.13 To date, the majority of such efforts has focused on either 
linear dimensionality reduction through PCA and regression through PLS,27 which provides 
insight into relationships between formulations and variables but has limited capacity to capture 
nonlinear behavior, or else artificial neural network “black box” models,43–45 which can capture 
nonlinear behavior but obscure interpretation of the structure of the model and dataspace. As the 
long-term goal of this research is to facilitate rational design of nanomedicine formulations, 
interpretation of the relationships between formulations is important. Accordingly, the 
dimensionality reduction approach was selected for this research, and paired with graph theory 
mapping to overcome the linearity limitations of PCA. 
A hybrid data mining approach was employed to deconvolute the complex polymer and drug 
relationships and develop QSPRs that describe release kinetics and encapsulation efficiency. We 
correlated antibiotic release properties from varying polyanhydride chemistries, encapsulated 
drug types, and drug loading within the nanoparticles. Through PCA analysis, we showed that 
release properties are dependent on both copolymer chemistry properties and drug properties, 
with polymer properties being more important. VIP analysis identified key polymer and drug 
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descriptors that predicted drug release and encapsulation properties, but PCA was insufficient to 
predict release behavior from these formulations. 
Graph theory was used to characterize the multilinear connectedness and similarity of 
formulations, which can guide selection of replacement formulations with similar release 
behavior. For example, it is expected that 20:80 CPH:SA rifampicin-loaded nanoparticles 
(Figure 2b) would demonstrate similar release behavior (including burst release, slope of release 
between days 2-7, and encapsulation efficiency) as 20:80 CPH:SA doxycycline-loaded 
nanoparticles (Figure 2a) based on their close connections and proximal distance on the map 
(Figure 7). Similarly, 20:80 CPTEG:CPH pyrazinamide-loaded nanoparticles (Figure 2d) would 
be expected to show large differences in release behavior from 20:80 CPH:SA chloramphenicol-
loaded nanoparticles (Figure 2c) due to the large number of lines needed to connect them and far 
distance on the map (Figure 7). The descriptors identified by VIP analysis were paired with the 
multilinear mapping from graph theory to generate predictive models for a priori screening of 
nanoparticle formulations with desired release kinetics and high encapsulation efficiency. 
The physicochemical properties of compounds influence their distribution, either in blood 
plasma or a polymer matrix. To this effect, VIP analysis (Figure 6) indicated that the descriptors 
most strongly correlated with release properties were both polymer and drug properties. This is 
expected, as favorable mixing thermodynamics allows distribution of the drugs inside the 
polymer device.10,46 In polyanhydride nanoparticles, such a distribution allows an erosion-
controlled release profile, which tends toward sustained release.9,11 In contrast, poor mixing 
between the polymer and drug induces thermodynamic partitioning of the drug into polymer 
microdomains and/or localization at the particle surface, which skews the release profile toward 
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a high-burst, diffusion-dominated regime.11 Many of these same drug properties were correlated 
with encapsulation efficiency, supporting the notion that polymer-drug mixing influences the 
carrying capacity of delivery devices. As empty polyanhydride nanoparticles have a moderately 
negative zeta potential,23 the strong negative correlation between zeta potential and encapsulation 
efficiency could reflect a strong surface localization of positively charged drugs. If this were the 
case, however, we would expect a strong positive correlation between zeta potential and the two-
hour burst release, which was not observed. Regardless, the predictive power of this descriptor 
could support the use of zeta potential as a quality control metric to ensure consistent 
encapsulation efficiencies of lead formulations. While it is not surprising that these drug 
properties affect encapsulation and release kinetics, this informatics analysis provides a sense of 
their relative impact. Reducing the data space in this way can help guide rational selection of 
antibiotic and polymer carrier pairs for nanomedicine formulations. These observations underline 
the complexity of these relationships and provide support for the use of data analytics approaches 
to enable rational design of nanomedicines.
It should be noted that we can only confidently make quantitative predictions in chemical spaces 
represented in our training data. While the additional testing of drugs containing sulfur, which 
was not represented in our training data, resulted in approximately no change in accuracy, 
materials that have unique behavior but with chemistries outside our training data may not be 
quantitatively described by this approach. However, even in these cases, our approach has 
significant impact. While the objective for the systems described by our training data is to predict 
properties with high accuracy, the objective for systems containing groups and elements not in 
our training data is to identify polymer and drug combinations which have the most promising 
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characteristics and identify where additional experiments are needed. This leads to an iterative 
approach where necessary experiments are identified, thus feeding back to the analysis.
From all of these results, we propose a framework for rational design and rapid testing of 
nanomedicine formulations (Scheme 1). In the first step, selected antibiotic drug candidates are 
encapsulated within nanoparticles of various polymer chemistries (potentially using high 
throughput techniques,23 as demonstrated in section 3.4), and characterization of size distribution 
by SEM and zeta potential is obtained. These nanoparticle characteristics, along with polymer 
properties and drug properties, can then be fed into the multilinear graph theory model to predict 
encapsulation efficiencies and release kinetics. Nanomedicine candidates that demonstrate 
insufficient encapsulation and/or undesirable drug release profiles can be discarded. The in vitro 
performance of the lead nanomedicine candidates that emerge from this step can then be 
validated using drug release kinetics assays. A feedback reformulation loop allows gradual 
optimization of nanomedicine formulations and iterative updates to the models when release 
behavior deviates from predictions. In theory, this framework could be expanded to include other 
performance metrics, including internalization by appropriate cells and biological efficacy. As 
this methodology uses standard polymer and nanoparticle characterization techniques used in 
nano-carrier drug delivery research and publicly available drug information, this approach could 
be expanded to include other types of polymeric materials and other classes of small molecule 
drugs. This data analytics framework constitutes the first steps toward the rational design of 
nanomedicine formulations for antimicrobial therapies.
Scheme 1. Data analytics framework for rapid nanomedicine design and screening.
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5. CONCLUSIONS
A multivariate data analytics approach was used to correlate drug release profiles from 
nanomedicine formulations based on different polyanhydride chemistries, encapsulated antibiotic 
drug type, and varying drug loading. We showed that both drug and polymer properties influence 
the drug encapsulation efficiency within the nanoparticles, the prevalence of burst in the drug 
release profile, and the slope of post-burst release. Polymer and drug properties that significantly 
impacted drug encapsulation efficiency and release kinetics were identified and defined a 
minimum descriptor set. The informatics analysis captured and preserved non-linear behavior 
governing relationships between drug type, polymer chemistry, and nanoparticle release 
properties, enabling interrogation of nanomedicine design pathways. We developed predictive 
Page 35 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
36
models for drug release kinetics of untested drugs, using data from the Drugbank database and 
nano-carrier characterization as inputs. Release kinetics predictions of two drugs containing 
atoms not included in the model showed good agreement with experimental results, validating 
the model and indicating its potential to virtually explore new polymer and drug pairs not 
included in training data set. The models were shown to be robust after inclusion of these new 
formulations in that there were no significant changes in the model regressions. This multilinear 
modeling approach provides the first steps towards development of a framework that can be used 
to rationally design nanomedicine formulations by selecting the appropriate carrier for a drug 
payload to program desirable release kinetics profiles. 
6. SUPPORTING INFORMATION
Dendrogram raw and processed input data; Principal component analysis raw input data; 
Chemical structures of drugs in validation data set; Release kinetics of drugs in validation data 
set.
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